Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)
Status: | Active, not recruiting |
---|---|
Conditions: | Cardiology, Ocular, Ocular |
Therapuetic Areas: | Cardiology / Vascular Diseases, Ophthalmology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/28/2019 |
Start Date: | January 15, 2019 |
End Date: | June 1, 2019 |
Drug Utilization Study in Patients Receiving Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)
A retrospective, non-interventional, observational, multi-center, drug utilization study to
be conducted in adult participants with visual impairment due to DME treated with Ozurdex
implants in Germany and Switzerland from 1 January 2015 to 1 September 2017.
be conducted in adult participants with visual impairment due to DME treated with Ozurdex
implants in Germany and Switzerland from 1 January 2015 to 1 September 2017.
Inclusion Criteria:
- Patient received at least two Ozurdex implants in the study eye to treat visual
impairment due to DME
- First Ozurdex implant injection occurred after 1 January 2015
- Patient was followed-up at the site for at least 12 months after the first Ozurdex
implant in the study eye
Exclusion Criteria:
- Participant received Ozurdex implants as part or during a clinical study
We found this trial at
1
site
Click here to add this to my saved trials